Stock Analysis, Dividends, Split History

RNVA / Rennova Health, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.59
Volume1,770,600.00
Market Cap ($M)1,770.00
Enterprise Value ($M)670.80
Book Value ($M)-129.95
Book Value / Share-0.04
Price / Book-13.62
NCAV ($M)-132.15
NCAV / Share-0.04
Price / NCAV-13.39
Share Statistics
Common Stock Shares Outstanding 19,750,844
Common Shares Outstanding 500,000,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)1.50
Return on Assets (ROA)-8.52
Return on Equity (ROE)3.71
Balance Sheet (mrq) ($M)
Assets16.25
Liabilities138.32
Quick Ratio0.04
Current Ratio0.05
Income Statement (mra) ($M)
Health Care Organization Patient Service Revenue Less Provision For Bad Debts4,619,473.00
Disposal Group Including Discontinued Operation Revenue1,933,569.00
Operating Income-16.08
Net Income-55.20
Earnings Per Share Basic-47.02
Earnings Per Share Basic And Diluted-47.02
Earnings Per Share Diluted-47.02
Cash Flow Statement (mra) ($M)
Cash From Operations-17.71
Cash from Investing-0.49
Cash from Financing-0.49
Identifiers and Descriptors
CUSIP759757107
Central Index Key (CIK)931059
Related CUSIPS
759757602

Split History

Stock splits are used by Rennova Health, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Community Health Arm to Divest AllianceHealth Deaconess

2018-06-27 zacks
Community Health Systems, Inc. (CYH - Free Report) recently announced that one of its units has signed a definitive agreement to sell 291-bed AllianceHealth Deaconess hospital in Oklahoma City, OK along with other related businesses to a subsidiary of INTEGRIS Health. The transaction is expected to close in the third quarter of 2018, subject to customary regulatory approvals and closing conditions. (64-0)

Community Health Sells Byrd Regional & Tennova Healthcare

2018-06-04 zacks
Community Health Systems, Inc. (CYH - Free Report) has completed the sale of 60-bed Byrd Regional Hospital and its associated assets to the subsidiaries of the Allegiance Health Management. The transaction took place on Jun 1, 2018. This move came in sync with the company’s planned divestitures, discussed on first-quarter 2018’s earnings call. In addition, the company sold 85-bed Tennova Healthcare Jamestown in Jamestown, TN along with its associated assets to units of Rennova Health, Inc. (79-0)

CUSIP: 759757107